Shares of Longboard Pharmaceuticals, Inc. surged on Thursday after the United States Food and Drug Administration (FDA) granted both Rare Pediatric Disease designation and Orphan Drug designation to its investigational drug, bexicaserin, for the treatment of Dravet syndrome. Pre-market trading saw shares rise by 4.2%, reaching $30.53, a continuation of the company’s upward trend over […]
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to acquire British-based GW Pharmaceuticals in a monumental $7.2 billion cash-and-stock transaction. This acquisition is set to create a powerhouse in the neuroscience field with a robust global commercial and operational footprint. Strategic Acquisition to Enhance Neuroscience Portfolio […]
Fintepla FDA approval : Zogenix has bagged approval from the US Food and Drug Administration (FDA) for Fintepla (fenfluramine) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients aged two years of age and older. Considered to be a life-threatening, rare and chronic type of epilepsy, Dravet syndrome is usually […]
US biotech company Stoke Therapeutics has secured orphan drug designation for its lead product candidate – STK-001 from the US Food and Drug Administration (FDA) for the treatment for Dravet syndrome. Considered to be a severe and progressive genetic epilepsy, Dravet syndrome is characterized by frequent, prolonged and refractory seizures that start within the first […]